Financial
Latest full-year results from official filings.
FY2025 revenue $176.0m (+40.0%); operating margin -36.4%; net loss $116.8m.
No debt; $280.2m cash.
- Official results release · HeartFlow · 31 Dec 2025
HeartFlow: risk summary
Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Adverse media
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
Apr 2026: HeartFlow sued rival Cleerly in US federal court (E.D. Texas), alleging patent infringement and misuse of its confidential information; Cleerly denies the claims. Jul 2025: HeartFlow filed for a US IPO.
- Patent infringement lawsuit alleges piracy of AI-driven medical technology · Epstein Becker Green Health Law Advisor · 8 Jun 2026
- Heartflow files for IPO · MedTech Dive · 21 Jul 2025
Cyber & information governance
Data breaches, cyber incidents, regulator action and assurance status.
No data breaches, cyber incidents or regulator action involving HeartFlow found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Regulatory & clinical safety
Recalls, safety notices, regulator action and clinical safety concerns.
No product recalls, FDA warning letters or safety notices involving HeartFlow found in HSH's search of the last 24 months.
Contract performance
Contract delivery, go-lives, terminations and disputes.
No notable contract disputes, terminations or troubled implementations involving HeartFlow found in HSH's search of the last 24 months.